Evoq Remedies Limited is an Indian pharmaceutical and agro-commodity enterprise currently undergoing a strategic transition. Historically operating as a **trader and commission agent**, the company is pivoting toward a diversified model encompassing **manufacturing, global exports, and specialized biopharmaceuticals**. While the company has secured significant international orders and expanded its capital base, it faces substantial headwinds related to **regulatory scrutiny, internal control weaknesses, and financial transparency**. --- ### **Core Business Verticals and Market Presence** Evoq Remedies operates across two primary domains, leveraging a lean operational model focused on procurement and distribution. * **Pharmaceuticals & Life Sciences:** * Trading of **Active Pharmaceutical Ingredients (APIs)**, generic drugs, and specialized formulations. * Strategic focus on **Generics, Biopharmaceuticals, and Biosimilars** to reduce time-to-market. * Expansion into **Digital Health Technologies** and advanced drug discovery. * **Agro-Commodities:** * Trading of grains, pulses, seeds, herbal products, and spices. * Processing and trading of high-value derivatives, including **castor oil, high-protein soya meal**, and various edible/non-edible oils. --- ### **Financial Performance and Capital Structure** The company has experienced significant volatility in its top-line performance, with a notable recovery in **FY 2024-25** following a sharp decline. However, profitability margins remain under pressure. #### **Three-Year Financial Summary** | Metric | FY 2024-25 | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | :--- | | **Total Revenue** | **₹14.17 Crore** | **₹4.05 Crore** | **₹20.39 Crore** | | **Profit Before Tax (PBT)** | **₹12.82 Lakhs** | **₹61.14 Lakhs** | **₹2.28 Crore** | | **Net Profit After Tax (PAT)** | **₹8.82 Lakhs** | **₹45.24 Lakhs** | **₹1.62 Crore** | #### **Aggressive Capital Expansion** To fund its transition from trading to manufacturing, the company has significantly increased its authorized and paid-up capital: * **Authorized Capital:** Increased from **₹16 Crore** to **₹42 Crore** (as of June 2025). * **Preferential Allotment (June 2024):** Allotted **1,13,00,000 Equity Shares** at **₹17.00 per share** (including a **₹7.00 premium**), raising approximately **₹22.60 Crore**. * **Convertible Warrants (April 2025):** Approved a proposal to raise up to **₹99.00 Crore** via warrants to non-promoter entities. --- ### **Strategic Related Party Framework** Evoq Remedies utilizes an extensive network of group entities to manage operational efficiency and resource access. For **FY 2025-26**, the company sought shareholder approval for material transactions (exceeding **10% of annual turnover**) with several partners: * **Solis Inventions Private Limited:** Up to **₹50 Crores** * **Vogue Lifestyle Private Limited:** Up to **₹50 Crores** * **Atlantis Exim:** Up to **₹50 Crores** * **Other Key Partners:** Solaris Agritech, Poshan Nutriwell, Recurso Wellness, Patron Exim, and EL Faro Ventures. --- ### **Growth Drivers and Global Expansion** * **Major Export Milestone:** In **January 2024**, the company secured a landmark export order worth **₹136 Crores** from **Marlexx Pharma Inc.**, signaling a shift toward international markets. * **Operational Realignment:** In **August 2025**, the board withdrew proposals to acquire **Poshan Nutriwell Private Limited (PNPL)** and **Spazio Formulations Limited (SFL)** via equity swaps, citing changing market conditions and a preference for organic growth. * **Infrastructure:** The registered office was relocated to **Science City Road, Ahmedabad**, to support a larger workforce and expanding operations. --- ### **Regulatory Scrutiny and Compliance Risks** The company is currently navigating a complex regulatory environment, with statutory auditors expressing an inability to confirm a "true and fair view" of the financial statements. * **SEBI Investigations:** * **July 2024:** Summons received regarding concerns over the preparation of financial statements. * **November 2024:** Show Cause Notice regarding the utilization of **₹19.21 Crore** raised through preferential allotment. * **Tax Litigation:** * **GST Demand:** An order for **₹6.55 Crore** (FY 2017-18) is currently under appeal. * **Income Tax:** Disputed demands of **₹1.4 Crore** plus interest remain unrecorded in the books. * **Internal Control Failures:** * **Audit Trail:** Non-compliance with **Section 128(5)** regarding accounting software edit logs. * **Internal Audit:** Failure to conduct internal audits for **FY 2024-25** despite statutory requirements. * **Inventory:** Lack of physical verification at the reporting date; a **50% provision (₹1.56 Crore)** was made for obsolescence. --- ### **Balance Sheet Vulnerabilities** The company’s financial position is characterized by high levels of advances and unconfirmed balances. | Risk Category | Amount | Description | | :--- | :--- | :--- | | **Related Party Loans** | **₹25.06 Crore** | Loans to **9 related parties** without specified repayment terms. | | **Supplier Advances** | **₹10.65 Crore** | Advances subject to confirmation; recoverability unverified. | | **Total Current Loans** | **₹32.66 Crore** | Includes significant exposure to related party entities. | | **Stale Debtors** | **₹75.26 Lakhs** | Long-outstanding balances, primarily from related parties. | | **Unpaid Statutory Dues** | **₹38.23 Lakhs** | Outstanding **TDS/TCS** collections not yet deposited. | --- ### **Market Outlook and Operational Threats** * **Competitive Pressures:** The pharmaceutical trading segment is marked by intense price competition, leading to margin erosion. * **Supply Chain & Geopolitics:** Operations are vulnerable to **Middle East tensions** and inflationary pressures in developed markets, which impact global trade flows. * **Talent Acquisition:** The company faces challenges in sourcing the specialized technical talent required for its transition into manufacturing and R&D. * **Product Integrity:** Risks associated with counterfeit drugs and stringent international regulatory standards remain a primary concern for the export business.